The Gloria Borges WunderGlo Foundation has given $1.1-Million Dollars directly to research funding for the cure of colorectal cancer in only their sixth year as an organization, through 100% grass-roots funding with no major donor or sponsor.

 

The Wunder Project is a movement that was created by one doctor and one patient. A movement to get every person involved to change the face of cancer. The Gloria Borges WunderGlo Foundation continues this movement on a mission to fund vital research for the cure of colorectal cancer. Contrary to popular belief, it can be cured. The only thing standing in the way between patients and a cure is money, bureaucracy, and politics.

 

The Wunder Project is creative, forward-thinking, and aggressive. The Wunder Project will not back down until we have raised every last cent of the $250 MILLION DOLLARS NEEDED FOR THE CURE and we will ensure that the process will not be held up by inefficiency, middlemen, or red tape. Yes, finding the cure will be nothing short of miraculous. But this is a miracle that we can achieve and a miracle from which we can all benefit. YOU CAN BE PART OF THAT MIRACLE. EVERY PERSON, EVERY DOLLAR, EVERY DISCUSSION COUNTS. You were born to kick cancer’s ass – join Dr. Heinz-Josef Lenz, our founder, Gloria Borges, and The WunderGlo Foundation in our audacious mission to cure colon cancer.  CANCER, YOUR TIME IS UP!

 

•  $1.1 Million Dollars in Grants directed to Dr. Heinz-Josef Lenz at USC-Norris Comprehensive Cancer Center and to Dr. Christina Curtis at Stanford University Medical School. The Stanford grant targets urgent work/understanding the mechanisms of colorectal cancer progression.

 

•  THE WUNDER PROJECT RESEARCH -WunderGlo Foundation Funded Research, credited since 2015, has been published in 17-peer reviewed research papers, including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and Molecular Cancer Therapeutics.

 

•  The WunderGlo Foundation grants to USC-Norris Comprehensive Cancer Center and established a strategic partnership with Stanford University Medical School. The Stanford grant was directed to Dr. Christina Curtis, who’s important work is focused on understanding and characterizing the genomic determinants and dynamics of metastatic colorectal cancer towards the goal of earlier detection and intervention, as well as improved treatment stratification.

 

•  In 2016, through Wunder Project funding, new biomarker patents have been filed at USC- Norris Comprehensive Cancer Center.

 

2018

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

2017

Tandem Repeat Variation Near the HIC1 (Hypermethylated in Cancer 1) Promoter Predicts Outcome of Oxaliplatin-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/ Bevacizumab or FOLFIRI/Cetuximab

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials

2016

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection

 

2015

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach